Last reviewed · How we verify

Gardnerella Vaginalis Bacterial Vaginosis — Treatment Landscape & Competitive Intelligence

Gardnerella Vaginalis Bacterial Vaginosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gardnerella Vaginalis Bacterial Vaginosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Klaron SULFACETAMIDE Merck & Co. Sulfonamide Antibacterial Dihydrofolate reductase 1945-01-01
Sulfabenzid SULFABENZAMIDE Johnson & Johnson sulfabenzamide 1945-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Johnson & Johnson · 1 drug in Gardnerella Vaginalis Bacterial Vaginosis
  2. Merck & Co. · 1 drug in Gardnerella Vaginalis Bacterial Vaginosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gardnerella Vaginalis Bacterial Vaginosis:

Cite this brief

Drug Landscape (2026). Gardnerella Vaginalis Bacterial Vaginosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gardnerella-vaginalis-bacterial-vaginosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing